Journal of Diagnostics Concepts & Practice ›› 2023, Vol. 22 ›› Issue (05): 441-447.doi: 10.16150/j.1671-2870.2023.05.004
• Original articles • Previous Articles Next Articles
FAN Zhenjia, ZHAO Juntao, ZHOU Jiakuan, LI Zhanquan, WAN Yinglei()
Received:
2023-09-21
Online:
2023-10-25
Published:
2024-03-15
CLC Number:
FAN Zhenjia, ZHAO Juntao, ZHOU Jiakuan, LI Zhanquan, WAN Yinglei. Application value of ST2 combined with CEA and CYFRA211 in diagnosis of early non-small cell lung cancer[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(05): 441-447.
Table 1
Concentration levels of ST2, CEA, CYFRA211, and their combination detection in the healthy population group, benign lung disease group, and early lung cancer group [median (upper quartile, lower quartile)] and difference analysis
groups | n | ST2 | CEA | CYFRA211 | Combination detection |
---|---|---|---|---|---|
Lung cancer stage Ⅰ | 91 | 69.1(51.4,90.4) | 1.60(1.09,2.41) | 1.18(0.81,1.75) | 16.8(12.3,22.1) |
Benign diseases | 50 | 42.7(29.5,62.4)a) | 1.49(1.08,2.77) | 1.23(0.80,1.79) | 11.4(8.1,16.3) |
Healthy people | 50 | 10.7(8.3,16.5)a),b) | 1.24(0.85,1.76) | 1.07(0.78,1.54 | 4.2(3.3,5.2) |
Healthy people vs Benign diseases | P<0.001 | P=0.010 | P=0.086 | P<0.001 | |
Benign diseases vs Lung cancer stage Ⅰ | P<0.001 | P=0.995 | P=0.368 | P=0.001 | |
Healthy people vs Lung cancer stage Ⅰ | P<0.001 | P=0.002 | P=0.006 | P<0.001 |
Table 2
Relationship between ST2, CEA, CYFRA211 and clinical pathological characteristics of lung cancer patients
Indice | N | ST2 | CEA | CYFRA211 | |||||
---|---|---|---|---|---|---|---|---|---|
Mean | P value | Mean | P value | Mean | P value | ||||
Age | 0.066 | 0.032 | 0.006 | ||||||
<60 | 35 | 63.3 | 1.85 | 1.26 | |||||
≥60 | 77 | 77.3 | 4.69 | 1.66 | |||||
Sex | 0.177 | 0.065 | 0.022 | ||||||
Male | 58 | 79.0 | 3.85 | 1.75 | |||||
Female | 54 | 66.5 | 3.76 | 1.29 | |||||
Degree of tumor differentiation | 0.820 | 0.032 | 0.358 | ||||||
Medium and high differentiation | 53 | 70.42 | 1.99 | 1.42 | |||||
Poorly differentiated | 59 | 75.23 | 5.44 | 1.63 | |||||
Lung cancer types | 0.144 | 0.084 | 0.017 | ||||||
Adenocarcinoma | 96 | 70.64 | 3.91 | 1.44 | |||||
Squamous cell carcinoma | 14 | 85.83 | 3.37 | 2.03 | |||||
TNM classification | 0.472 | <0.001 | 0.124 | ||||||
Stage Ⅰ | 91 | 72.87 | 2.36 | 1.51 | |||||
Stage Ⅱ, stage Ⅲ, and stage Ⅳ | 21 | 73.34 | 10.07 | 1.63 | |||||
Tumor size (T) | 0.025 | 0.005 | 0.052 | ||||||
<3 cm (T1) | 95 | 71.12 | 3.43 | 1.47 | |||||
≥3 cm (T2+T3+T4) | 17 | 83.24 | 5.94 | 1.82 | |||||
Involvement of lymph nodes (N) | 0.161 | 0.002 | 0.976 | ||||||
Without lymph node metastasis (N0) | 102 | 74.81 | 2.52 | 1.55 | |||||
With lymph node metastasis (N1+N2+N3) | 10 | 54.03 | 16.90 | 1.32 | |||||
Spread through air spaces (STAS) | 0.661 | <0.001 | 0.157 | ||||||
Without | 81 | 72.67 | 1.96 | 1.46 | |||||
With | 31 | 73.70 | 8.63 | 1.71 | |||||
Tumor location type | 0.483 | 0.549 | 0.108 | ||||||
Peripheral type | 103 | 71.71 | 3.93 | 1.47 | |||||
Central type | 9 | 87.14 | 2.36 | 2.13 | |||||
Single or multiple type | 0.709 | 0.804 | 0.446 | ||||||
Single type | 104 | 73.09 | 3.90 | 1.56 | |||||
Multiple primary lung cancer | 8 | 71.23 | 2.66 | 1.14 | |||||
Pleural invasion | 0.880 | <0.001 | 0.174 | ||||||
Without | 89 | 72.33 | 2.14 | 1.52 | |||||
With | 23 | 75.37 | 10.26 | 1.57 |
Table 3
Sensitivity, specificity, positive and negative predictive value, Jordan index, area under ROC curve and cut-off value for single and combined detection of ST2, CEA and CYFRA211
Indice | Sensitivity(%) | Specificity(%) | Positive predictive value(%) | Negative predictive value(%) | Yoden index | AUC | Cut-off value |
---|---|---|---|---|---|---|---|
ST2 | 89.0 | 98.0 | 98.7 | 83.1 | 0.871 | 0.957 | 25.0 |
CEA | 46.2 | 80.0 | 80.8 | 44.9 | 0.267 | 0.660 | 1.8 |
CYFRA211 | 17.6 | 96.0 | 88.9 | 39.0 | 0.157 | 0.570 | 2.0 |
Joint detection | 92.3 | 98.0 | 97.7 | 87.3% | 0.904 | 0.973 | 6.4 |
[1] | WANG Z Z, ZHENG Y. Lung cancer worldwide and in China from 1990 to 2020:prevalence and prevention measures[J]. J Diagn Concepts Pract, 2023, 22(1):1-7. |
[2] | 张捷, 常莉, 王丽, 等. 非小细胞肺癌放疗联合免疫治疗相关进展[J]. 肿瘤, 2022, 42(9):667-672. |
ZHANG J, CHANG L, WANG L, et al. Progress in radiotherapy combined with immunotherapy for non-small cell lung cancer[J]. Tumor, 2022, 42(9):667-672. | |
[3] |
TSOI K K, HIRAI H W, CHAN F C, et al. Cancer burden with ageing population in urban regions in China: projection on cancer registry data from World Health Organization[J]. Br Med Bull, 2017, 121(1):83-94.
doi: 10.1093/bmb/ldw050 URL |
[4] | 中华医学会呼吸病学分会. 早期肺癌诊断中国专家共识(2023年版)[J]. 中华结核和呼吸杂志, 2023, 46(01):1-18. |
Chinese Thoracic Society. Chinese expert consensus on diagnosis of early lung cancer (2023 Edition)[J]. Chin J Tuberc Respir Dis, 2023, 46(01):1-18. | |
[5] | 韩群啸, 鲍国林, 刘义庆. 肺癌早期诊断研究进展[J]. 中国医药, 2023, 18(5):761-764. |
HAN Q X, BAO G L, LIU Y Q. Research progress on early diagnosis of lung cancer[J]. Chin Med, 2023, 18(5):761-764. | |
[6] | 缪怡静, 姚叶林, 林志坚, 等. CEA、CA125、CYFRA211、NSE肿瘤标志物联合检测对肺癌的鉴别诊断效果[J]. 吉林医学, 2022, 43(11):3082-3084. |
MIAO Y J, YAO Y L, LIN Z J, et al. The combined detection of CEA, CA125, CYFRA211, and NSE tumor markers in the differential diagnosis of lung cancer[J]. Jilin Med J, 2022, 43(11):3082-3084. | |
[7] |
LEI S, JIN J, ZHAO X, et al. The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy[J]. Exp Biol Med (Maywood), 2022, 247(20):1810-1818.
doi: 10.1177/15353702221102094 URL |
[8] | 张颖, 陈芊, 石玉霞, 等. 新辅助免疫治疗在非小细胞肺癌中的应用进展[J]. 安徽医学, 2022, 43(2):240-243. |
ZHANG Y, CHENG Q, SHI Y X, et al. Progress in the application of neoadjuvant immunotherapy in non-small cell lung cancer[J]. Anhui Med, 2022, 43(2):240-243. | |
[9] | 罗玲, 王江红. 支气管肺泡灌洗液SCCA、CYFRA21-1、CEA联合检测在肺癌诊断中的价值[J]. 重庆医科大学学报, 2010, 35(11):1716-1718. |
LUO L, WANG J H. Combined determination of SCCA,CYFRA21-1 and CEA in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. J Chongqing Univ, 2010, 35(11):1716-1718. | |
[10] |
CHEN F, WANG X Y, HAN X H, et al. Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease[J]. Int J Clin Exp Med, 2015, 8(7):11295-11300.
pmid: 26379938 |
[11] | 赵珺涛, 陆炜, 刘锦燕, 等. 血清肿瘤标志物CKAP4在肺癌辅助诊断中的应用[J]. 标记免疫分析与临床, 2022, 29(11):1832-1837,1911. |
ZHAO J T, LU W, LIU J Y, et al. The application of cytoskeleton-associated protein 4 in the auxiliary diagnosis of lung cancer[J]. Labeled Immunoassays & Clin Med, 2022, 29(11):1832-1837,1911. | |
[12] |
HOMSAK E, GRUSON D. Soluble ST2: a complex and diverse role in several diseases[J]. Clin Chim Acta, 2020, 507:75-87.
doi: S0009-8981(20)30166-2 pmid: 32305537 |
[13] | 司盼. IL-33/ST2L通路调节CD4+T细胞分化对缺血性神经元的保护性研究[D]. 河南: 郑州大学, 2018. |
SI P. IL-33/ST2L signal ameliorates neuron-apoptosis by modulating CD4+T lymphocytes differentiation[D]. Zhengzhou University, 2018. | |
[14] | 闫心怡, 张岩, 孙家梅, 等. 肺癌患者手术前后ST2水平变化及临床意义[J]. 中国免疫学杂志, 2022, 38(23):2902-2905,2911. |
[1] | 王泽洲, 郑莹. 1990年至2020年间全球及我国肺癌的发病流行趋势及防控措施[J]. 诊断学理论与实践, 2023, 22(1):1-7. |
[14] | YAN X Y, ZHANG Y, SUN J M, et al. ST2 changes and its clinical significance in lung cancer patients before and after surgery[J]. Chin J Immunol, 2022, 38(23):2902-2905,2911. |
[15] |
WANG C, CHEN Z, BU X, et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer[J]. Biochem Biophys Res Commun. 2016; 479(3):461-468.
doi: 10.1016/j.bbrc.2016.09.081 URL |
[16] |
YANG Z, GAO X, WANG J, et al. Interleukin-33 enhanced the migration and invasiveness of human lung cancer cells[J]. Onco Targets Ther. 2018; 11:843-849.
doi: 10.2147/OTT URL |
[17] |
VITALI E, PICCINI S, TRIVELLIN G, et al. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors[J]. Mol Cell Endocrinol, 2021, 527:111226.
doi: 10.1016/j.mce.2021.111226 URL |
[18] | 王维飞, 何广思, 胡加海. 非小细胞肺癌患者六种血清指标的变化及其检测价值[J]. 中国临床研究, 2023, 36(6):849-855. |
WANG W F, HE G S, HU J H. Detection value of six serum indicators in non-small cell lung cancer patients[J]. Chin J Clin Res, 2023, 36(6):849-855. | |
[19] | 王继鹏, 李朋玲, 陈胜. Pokemon、miR-451、IFITM1在非小细胞肺癌组织中的表达及与病理特征的相关性[J]. 中国老年学杂志, 2023, 43(9):2079-2083. |
WANG J P, LI P L, CHEN S. The expression of Pokemon, miR-451, and IFITM1 in non-small cell lung cancer tissues and their correlation with pathological features[J]. Chin J Gerontol, 2023, 43(9):2079-2083. | |
[20] | ZHOU W, YANG Y, WANG Z, et al. Impact of HSP90α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients[J]. J Healthc Eng, 2021:6929971. |
[21] |
GEZELIUS E, BENDAHL P O, GALLO W, et al. Circulating levels of the cardiovascular biomarkers ST2 and adrenomedullin predict outcome within a randomized phase Ⅲ lung cancer trial (RASTEN)[J]. Cancers (Basel), 2022, 14(5):1307.
doi: 10.3390/cancers14051307 URL |
[1] | CHEN Guoqun, CAI Jiaodi. Interpretation of the Clinical Practice Guidelines for Non-small Lung Cancer (version 4 and version 5) of 2022 National Comprehensive Cancer Nerwork(NCCN) [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 8-13. |
[2] | ZHANG Hua, LU Wei, YANG Chengyi, XIANG Mingjie. Value of serum FBLN1 detection in diagnosis and prognosis prediction of colorectal cancer [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 462-465. |
[3] | DU Hailei, CHEN Ling, LUO Fangxiu, LI Yong, CHENG Qijian, ZHU Lianggang, HANG Junbiao. The prognostic value of Beclin-1 and Bcl-2 and its relationship with pathological characteristics in patients with non-small cell lung cancer [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 258-263. |
[4] | GU Shengjia, CAO Qiqi, YAN Fuhua, YANG Wenjie. Quantitative assessment of therapy response of non-small cell lung cancer with dual-energy CT [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 526-532. |
[5] | . [J]. Journal of Diagnostics Concepts & Practice, 2015, 14(02): 150-154. |
[6] | . [J]. Journal of Diagnostics Concepts & Practice, 2013, 12(04): 462-465. |
[7] | . [J]. Journal of Diagnostics Concepts & Practice, 2013, 12(01): 57-61. |
[8] | . [J]. Journal of Diagnostics Concepts & Practice, 2012, 11(02): 167-171. |
[9] | . [J]. Journal of Diagnostics Concepts & Practice, 2002, 1(01): 28-30. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||